Skip to contentpdufa.bio

Dr. Reddy’s Laboratories: 12 Complete Response Letters

Page updated ·next FDA decision on the calendar ·Data as of Nov 21, 2026 10:10 PM ET

The FDA's CRL release (openFDA transparency/crl, last updated 2026-11-18; snapshot read 2026-11-21) holds 12 Complete Response Letters to this company, dated 2014 to 2025, on 5 applications; 3 of them received more than one. The FDA releases letters selectively, so this may not be every letter the company received. Printed in the release as: Dr. Reddy’s Laboratories Limited (4); Dr. Reddy’s Laboratories SA (2); Dr. Reddy’s Laboratories, Inc (2); Dr. Reddy’s Laboratories, Limited- (2); Dr. Reddy’s Laboratories, Inc. (1); Dr. Reddy’s Laboratories, SA (1).

Grouped on the company name as openFDA prints it, with capitalization, accents, punctuation and corporate-form words (Inc., LLC, Ltd., Limited, Corp., SA, USA and the like) ignored; each row shows the name as printed. A misspelled name forms its own group, and a letter printed with a heading or a bare corporate-form word where the name should be is on no company page, so a count here can be lower than the letters the release holds for a company. Facts only: no view on any outcome.

Letter dateApplicationName as printedopenFDA statusOrange Book approval after the letterSections the letter names
December 30, 2025BLA 761471Dr. Reddy’s Laboratories, Inc.Unapprovednot in the Orange Book (a BLA)Facility Inspections
October 16, 2025BLA 761376Dr. Reddy’s Laboratories SAUnapprovednot in the Orange Book (a BLA)Microbiology
April 19, 2024BLA 761376Dr. Reddy’s Laboratories SAUnapprovednot in the Orange Book (a BLA)Product Quality (Microbiology); Product Quality; Drug Substance; Microbiology
April 18, 2022NDA 210852Dr. Reddy’s Laboratories LimitedApprovedFrindovyx, June 7, 2023none read
November 6, 2020NDA 210852Dr. Reddy’s Laboratories LimitedApprovedFrindovyx, June 7, 2023none read
May 21, 2020NDA 210852Dr. Reddy’s Laboratories LimitedApprovedFrindovyx, June 7, 2023none read
November 20, 2019NDA 210852Dr. Reddy’s Laboratories LimitedApprovedFrindovyx, June 7, 2023none read
May 3, 2019NDA 210852Dr. Reddy’s Laboratories, IncApprovedFrindovyx, June 7, 2023none read
July 24, 2018NDA 210852Dr. Reddy’s Laboratories, IncApprovedFrindovyx, June 7, 2023none read
August 30, 2016NDA 206966Dr. Reddy’s Laboratories, SAApprovedXeglyze, July 24, 2020none read
May 4, 2016NDA 206927/Original 1, NDA 206927Dr. Reddy’s Laboratories, Limited-ApprovedBortezomib, October 4, 2019none read
December 17, 2014NDA 206927/Original 1, NDA 206927Dr. Reddy’s Laboratories, Limited-ApprovedBortezomib, October 4, 2019none read

How each column is made: the letter date and the PDF are the FDA's release; "openFDA status" is openFDA's approval_status field as released; "Orange Book approval" is the earliest approval date the FDA's Orange Book products file (FDA files dated 2026-11-13) lists for the NDA, shown when it falls after the letter date and the letter is not on a supplement; BLAs are not in the Orange Book, so no date is shown for them; "sections" are the letter's own deficiency headings read from its PDF text layer, for letters dated 2024 or later whose PDF holds no other letter from the release ("none read" otherwise, or where no heading could be read).

Every company in the release · facts from all released CRLs · every released letter